New study tests fasting and Weight-Loss drugs to shield hearts during prostate cancer treatment
NCT ID NCT07202247
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 22 times
Summary
This study looks at whether time-restricted eating (intermittent fasting) or GLP-1 medications (semaglutide and tirzepatide) can better protect the heart and metabolism of prostate cancer patients on hormone therapy compared to a standard heart-healthy diet. About 60 men aged 30-79 with prostate cancer and high heart disease risk will be enrolled. The goal is to find ways to reduce the increased risk of heart problems caused by hormone therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.